Overview

Allogenic Stem Cell Transplantation (SCT) With Non-myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL)

Status:
Completed

Trial end date:
2013-02-04

Target enrollment:

Participant gender:

Summary

To evaluate the use of ibritumomab tiuxetan (Zevalin) as part of the non myeloablative conditioning with melphalan, fludarabine and thiotepa in patients submitted to allogeneic transplantation of haematopoietic stem cells from family donor's peripheral blood.

Phase:

Phase 2

Details

Lead Sponsor:

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Treatments:

Antibodies, Monoclonal
Fludarabine
Melphalan
Rituximab
Thiotepa